<DOC>
	<DOCNO>NCT00956046</DOCNO>
	<brief_summary>The purpose study generate data immunogenicity safety monovalent H1N1 vaccine support development registration . Primary objective : - To describe immune response vaccine 21 day vaccination participant . - To describe antibody persistence eight month first vaccine administration use hemagglutination inhibition ( HAI ) method subset participant receive two half-doses either formulation 1 2 . - To describe immune response A/H1N1 strain use HAI method 21 day last vaccination 2010-2011 NH seasonal Trivalent Influenza Vaccine ( TIV ) administer 13 month first vaccination subset subject receive two half-doses either either formulation 1 2 A/H1N1 influenza vaccine primary series . - To describe safety profile vaccine participant .</brief_summary>
	<brief_title>A Study Swine-origin A/H1N1 Influenza Vaccines Healthy Europeans Children Aged 6 35 Months</brief_title>
	<detailed_description>All participant receive two injection randomized vaccine Day 0 Day 21 , respectively . A subset participant eligible receive two half-doses either formulation 1 2 also propose receive 2010-2011 Northern Hemisphere ( NH ) seasonal Trivalent Influenza Vaccine ( TIV ) 13 month first vaccination Follows : - Subjects less 36 month time TIV injection receive two half-doses additional sampling immunogenicity assessment ( one first TIV vaccination one 21 day last TIV vaccination ) . - Subjects age 36 month time TIV injection receive full TIV dose additional sampling immunogenicity assessment ( one TIV vaccination one 21 day TIV vaccination ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Inclusion Criteria : All subject Aged 6 35 month day inclusion Informed consent form sign dated parent ( ) legally acceptable representative Subject parent/legal representative able attend schedule visit comply trial procedure Completion vaccination accord national immunization schedule . Subjects ≥ 6 &lt; 24 month age Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg At Month 8 antibody persistence assessment : Having receive two halfdoses either formulation 1 2 vaccine Addendum 1 Informed Consent Form sign dated parent legally acceptable representative . At Visit 06 , subject eligible Antibody persistence evaluation receive Trivalent Influenza Vaccine ( TIV ) : Addendum 2 Informed Consent Form sign subject 's parents/legal representative . Exclusion Criteria : All subject Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine prior Day 42 blood sample Receipt blood bloodderived product past 3 month might interfere assessment immune response Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B antigen , Hepatitis C report parents/legal representative Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Thrombocytopenia contraindicate intramuscular ( IM ) vaccination report parents/legal representative Bleeding disorder receipt anticoagulants 3 week precede inclusion contraindicate IM vaccination Chronic illness opinion Investigator stage might interfere trial conduct completion Family member employee Investigator Previous participation trial investigate vaccine swineorigin A/H1N1 influenza strain Confirmed infection swineorigin A/H1N1 influenza strain ( different seasonal strain ) 2009 Febrile illness ( temperature ≥ 38.0°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment Receipt allergy shot and/or seasonal allergy medication 7day period prior enrollment ( vaccination ) , schedule receive allergy shot and/or seasonal allergy medication 7day period enrollment ( vaccination ) Subjects ≥ 6 &lt; 24 month age History seizure At Month 8 , antibody persistence assessment : Subjects receive , context pandemic immunization program , another A/H1N1 pandemic influenza vaccine Investigational Medicinal Products .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemic Flu</keyword>
	<keyword>Swine-origin A/H1N1 Influenza</keyword>
	<keyword>Swine-origin Influenza Virus</keyword>
	<keyword>Infants</keyword>
</DOC>